Klaus-Michael Debatin

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

Blood

Biomedicines

The Journal of experimental medicine

Pharmaceuticals (Basel, Switzerland)

Ulm University Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Ulm University Medical Center

Germany

Chairman of the Department of Pediatrics and Adolescent Medicine :: Pediatrics and Adolescent Medicine

Ulm University

Germany

Professor of Pediatrics :: Pediatrics and Adolescent Medicine

Publications

Victor G Lui, Manfred Hoenig, Berenice Cabrera-Martinez, Ryan M Baxter, Josselyn E Garcia-Perez, Olivia Bailey, Atanu Acharya, Karl Lundquist, Jesusa Capera, Paul Matusewicz, Frederike A Hartl, Marco D'Abramo, Josephine Alba, Eva-Maria Jacobsen, Doris Niewolik, Myriam Lorenz, Ulrich Pannicke, Ansgar S Schulz, Klaus-Michael Debatin, Wolfgang W A Schamel, Susana Minguet, James C Gumbart, Michael L Dustin, John C Cambier, Klaus Schwarz, Elena W Y Hsieh
A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation. The Journal of experimental medicine 221 (1) (2023)
Mike-Andrew Westhoff, Marie Schuler-Ortoli, Daniela Zerrinius, Amina Hadzalic, Andrea Schuster, Hannah Strobel, Angelika Scheuerle, Tiana Wong, Christian Rainer Wirtz, Klaus-Michael Debatin, Aurelia Peraud
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy. Pharmaceuticals (Basel, Switzerland) 15 (1) (2022)
Juan Lázaro, Helia Judith Pimentel-Gutiérrez, Anton Gauert, Anja I H Hagemann, Jassi Lena Eisenschmid, Nicola Goekbuget, Binje Vick, Irmela Jeremias, Felix Seyfried, Lüder Hinrich Meyer, Klaus-Michael Debatin, Kathrin Richter, Miriam Bultmann, Martin Neumann, Sonja Haenzelmann, Hubert Serve, Kathy Astrahantseff, Michael A Rieger, Cornelia Eckert, Claudia D Baldus, Lorenz Bastian
Inhibiting Casein Kinase 2 Sensitizes Acute Lymphoblastic Leukemia Cells to Venetoclax Via MCL1 Degradation. Blood advances (2021)
Elena Boldrin, Enrico Gaffo, Alexandra Niedermayer, Judith M Boer, Martin Zimmermann, Dieter Weichenhan, Rainer Claus, Vera Münch, Qian Sun, Stefanie Enzenmüller, Felix Seyfried, Salih Demir, Julia Zinngrebe, Gunnar Cario, Martin Schrappe, Monique L Den Boer, Christoph Plass, Klaus-Michael Debatin, Geertruij Te Kronnie, Stefania Bortoluzzi, Lüder Hinrich Meyer
MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood 138 (20) (2021)
Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, Sascha Endres, Philipp M Roessner, Felix Seyfried, Claudia Walliser, Martin Wist, Jialei Qi, Eugen Tausch, Daniel Mertens, Judith A Fox, Klaus-Michael Debatin, Lueder Hinrich Meyer, Pietro Taverna, Martina Seiffert, Peter Gierschik, Stephan Stilgenbauer
Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood (2021)
Hannah Strobel, Tim Baisch, Rahel Fitzel, Katharina Schilberg, Markus D Siegelin, Georg Karpel-Massler, Klaus-Michael Debatin, Mike-Andrew Westhoff
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 7 (3) (2019)
Julia Zinngrebe, Ferdinand Schlichtig, Johann M Kraus, Malcolm Meyer, Elena Boldrin, Hans A Kestler, Lüder-Hinrich Meyer, Pamela Fischer-Posovszky, Klaus-Michael Debatin
Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia. International journal of cancer 146 (11) (2019)
Klaus-Michael Debatin
HSCT cures ADA2 deficiency. Blood 130 (24) (2018)

Klaus-Michael Debatin.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Klaus-Michael Debatin